Design Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Design Therapeutics's estimated annual revenue is currently $8.4M per year.
- Design Therapeutics's estimated revenue per employee is $108,231
- Design Therapeutics's total funding is $170.7M.
- Design Therapeutics's current valuation is $882.3M. (January 2022)
Employee Data
- Design Therapeutics has 78 Employees.
- Design Therapeutics grew their employee count by 24% last year.
Design Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chairman and CEO | Reveal Email/Phone |
2 | Chief Accounting Officer | Reveal Email/Phone |
3 | VP Product Development | Reveal Email/Phone |
4 | VP Clinical Operations | Reveal Email/Phone |
5 | SVP Technology and Research | Reveal Email/Phone |
6 | VP, Strategy and Operations | Reveal Email/Phone |
7 | Controller | Reveal Email/Phone |
8 | Head HR and People | Reveal Email/Phone |
9 | Director, Drug Discovery Sciences, Chemistry at Design Therapeutics | Reveal Email/Phone |
10 | Sr. Director, Computational Chemistry | Reveal Email/Phone |
Design Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $53.7M | 267 | 16% | N/A | N/A |
#2 | $53.1M | 264 | 21% | N/A | N/A |
#3 | $69.1M | 344 | 26% | N/A | N/A |
#4 | $22.1M | 110 | -10% | N/A | N/A |
#5 | $151.8M | 755 | 11% | N/A | N/A |
#6 | $63.9M | 318 | 13% | N/A | N/A |
#7 | $29.9M | 149 | 13% | N/A | N/A |
#8 | $1.7M | 17 | -6% | $114.3M | N/A |
#9 | $6.8M | 34 | -6% | N/A | N/A |
#10 | $12.5M | 62 | -9% | N/A | N/A |
What Is Design Therapeutics?
$170.7M
Total Funding
78
Number of Employees
$8.4M
Revenue (est)
24%
Employee Growth %
$882.3M
Valuation
N/A
Accelerator
Design Therapeutics News
The 57 rating InvestorsObserver gives to Design Therapeutics Inc (DSGN) stock puts it near the top of the Biotechnology industry.
Analysts expect Design Therapeutics, Inc. (NASDAQ:DSGN Get Rating) to post earnings of ($0.22) per share for the current fiscal quarter,...
Design Therapeutics is a clinical-stage biotechnology company developing a new class of therapies based on its platform of GeneTAC gene...
Biotech company Design Therapeutics has set terms to raise as much as $240 million in its IPO. The company plans to sell 12 million shares for between $18 and $20 each in the offering. Design's top shareholders include SR One (10% post-IPO stake), Quan Funds (8.8%) and Cormorant (8.1%). View de ...
Other Companies in
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $7.5M | 78 | 28% | $824.7B |
#2 | $19M | 78 | -8% | N/A |
#3 | $25.2M | 78 | 15% | N/A |
#4 | $22.6M | 78 | -4% | N/A |
#5 | $22.6M | 78 | 4% | N/A |